C4 Therapeutics (CCCC) Equity Ratio: 2019-2025
Historic Equity Ratio for C4 Therapeutics (CCCC) over the last 5 years, with Sep 2025 value amounting to 0.58.
- C4 Therapeutics' Equity Ratio fell 9.87% to 0.58 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.58, marking a year-over-year decrease of 9.87%. This contributed to the annual value of 0.62 for FY2024, which is 5.50% down from last year.
- C4 Therapeutics' Equity Ratio amounted to 0.58 in Q3 2025, which was down 0.92% from 0.59 recorded in Q2 2025.
- In the past 5 years, C4 Therapeutics' Equity Ratio ranged from a high of 0.79 in Q2 2021 and a low of 0.58 during Q3 2025.
- In the last 3 years, C4 Therapeutics' Equity Ratio had a median value of 0.65 in 2024 and averaged 0.63.
- As far as peak fluctuations go, C4 Therapeutics' Equity Ratio surged by 215.37% in 2021, and later fell by 12.68% in 2022.
- Over the past 5 years, C4 Therapeutics' Equity Ratio (Quarterly) stood at 0.77 in 2021, then decreased by 12.68% to 0.67 in 2022, then fell by 2.61% to 0.65 in 2023, then declined by 5.50% to 0.62 in 2024, then dropped by 9.87% to 0.58 in 2025.
- Its Equity Ratio stands at 0.58 for Q3 2025, versus 0.59 for Q2 2025 and 0.61 for Q1 2025.